Too much AKT turns PAX3-FKHR dead: a prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma.
about
What is new in the biology and treatment of pediatric rhabdomyosarcoma?Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.MicroRNA dysregulation in rhabdomyosarcoma: a new player enters the game.The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.
P2860
Too much AKT turns PAX3-FKHR dead: a prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Too much AKT turns PAX3-FKHR d ...... for alveolar rhabdomyosarcoma.
@en
Too much AKT turns PAX3-FKHR d ...... for alveolar rhabdomyosarcoma.
@nl
type
label
Too much AKT turns PAX3-FKHR d ...... for alveolar rhabdomyosarcoma.
@en
Too much AKT turns PAX3-FKHR d ...... for alveolar rhabdomyosarcoma.
@nl
prefLabel
Too much AKT turns PAX3-FKHR d ...... for alveolar rhabdomyosarcoma.
@en
Too much AKT turns PAX3-FKHR d ...... for alveolar rhabdomyosarcoma.
@nl
P2860
P356
P1433
P1476
Too much AKT turns PAX3-FKHR d ...... for alveolar rhabdomyosarcoma.
@en
P2093
Asoke K Mal
Mathivanan Jothi
P2860
P304
P356
10.18632/ONCOTARGET.713
P407
P577
2012-10-01T00:00:00Z